<DOC>
	<DOC>NCT01246336</DOC>
	<brief_summary>Parkinson's disease is diagnosed clinically, because biomarkers that may help in diagnosis and differential diagnosis are not yet available. Exhaled breath testing may yield a "breath-print" that can be used to distinguish healthy and diseased states.</brief_summary>
	<brief_title>Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<criteria>Patients with Parkinsonism Severe dementia</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Parkinson's disease, Parkinsonism</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Exhaled breath</keyword>
	<keyword>Nanothechnology</keyword>
</DOC>